Three phase II trials adopting this strategy are currently recruiting patients: these studies are testing olaparib alone (NCT03212274) or in combination with ceralasertib (AZD6738-NCT03878095) or durvalumab (NCT03991832) in both IDH1 and IDH2 mutant recurrent CCA. Here, IDH2 is linked to cholangiocarcinoma.